Humanoid Global Propels RideScan Towards Robot Safety Innovations
Insights into Humanoid Global's Recent Developments
Vancouver, BC & Edinburgh, Scotland — Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), a prominent player in the investment sector focusing on humanoid robotics and embodied AI, has shared exciting updates regarding its subsidiary, RideScan Ltd.
RideScan's Technological Advancements
RideScan has made significant strides by filing its foundational patent application with the United Kingdom Intellectual Property Office. This application aims to safeguard RideScan's innovative approach to independent risk scoring and anomaly detection within robotics. By securing this patent-pending technology, RideScan strengthens its position as a reliable leader in the robotic safety domain, facilitating applications in mission-level risk assessment and proactive maintenance.
Behavioral Assessments and Intelligent Insights
The organization is launching pilot projects across various ecosystems, including humanoid, robotic, and industrial settings. These pilot deployments are designed to showcase RideScan’s ability to deliver independent, AI-driven evaluations of robot health and performance, enhancing safety and reliability on a large scale.
Commitment to Safe Robotics
“At RideScan, our mission is to ensure that every robot operates safely and reliably,” stated Dr. Nandakumar, the CEO of RideScan. “Filing our foundational patent is a monumental step towards safeguarding the technology behind our vision. We believe that our upcoming pilots will demonstrate how this innovation revolutionizes global robot deployment.”
Building Partnerships for Future Growth
To accelerate this mission, RideScan is forming a select group of ten organizations to integrate RideScan’s API across various robotics platforms. This collaboration comprises engineers and teams from both research institutions and large corporations in the robotics sector. The goal of this cohort is to exhibit RideScan's capability to minimize downtime through preemptive issue identification, improve operational safety with independent health checks, and uncover hidden problems that conventional monitoring might miss.
Securing Funding for Development
Moreover, RideScan has recently secured £50,000 from the Innovate UK Growth Catalyst Early Stage: New Innovators grant, aiding its further expansion and commercialization efforts, with execution slated to commence. An additional investment of £40,000 from a European angel syndicate specializing in deep tech also bolsters their funding. This syndicate includes research scientists from a Fortune 500 company that focuses on artificial intelligence research.
Humanoid Global's Perspective on Progress
Shahab Samimi, the CEO of Humanoid Global, expressed enthusiasm about RideScan's ongoing advancements, ranging from patent filings to the initiation of pilot cohorts, alongside garnering substantial grants and investments. “This progress not only strengthens our portfolio’s commitment to safe, scalable robotics but also cements RideScan’s role in facilitating trustworthy AI-driven deployments globally,” he asserted.
About Humanoid Global Holdings Corp.
Humanoid Global Holdings Corp. (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF) takes pride in being a publicly traded investment issuer that focuses on assembling a portfolio of leading companies in the humanoid robotics and embodied AI sectors. The Company is dedicated to investing in and fostering the growth of pioneering technologies.
Humanoid Global acts as a global investment platform that provides both liquidity and access to an actively managed portfolio spanning the entire value chain of this dynamic ecosystem. By ensuring support in terms of capital, strategic consultation on go-to-market initiatives, and connections to customers, suppliers, and strategic partners, Humanoid Global is poised to elevate the industry further.
To learn more about our initiatives and the evolving landscape of robotics, you can reach out via:
Shahab Samimi
Chief Executive Officer
finance@humanoidglobal.ai
info@humanoidglobal.ai
(604) 602-0001
CSE:ROBO
OTCQB:RBOHF
FWB:0XM1
Frequently Asked Questions
What is RideScan’s recent patent application about?
RideScan's patent application focuses on its unique technology for independent risk scoring and anomaly detection in robotics.
What are the aims of RideScan's pilot deployments?
The pilots are designed to showcase RideScan's capabilities in providing AI-driven insights on robot health and performance.
How does RideScan plan to enhance safety in robotics?
By identifying issues before they escalate and performing robot health checks, RideScan aims to improve operational safety reliably.
Who are the partners involved in RideScan's cohort?
The cohort includes engineers and teams from both academic and corporate sectors within the robotics industry.
What funding has RideScan received for its technology growth?
RideScan received £50,000 from an Innovate UK grant and £40,000 from a European angel syndicate specializing in deep tech investments.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
